Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2019 Oct 30;29(1):31–38. doi: 10.1158/1055-9965.EPI-19-0538

Figure 3.

Figure 3.

Sensitivity and specificity of the HPV tests to p16 IHC. A, Visual representation of HPV-positive cases by each test in relation to p16 positivity. Forest plots of computed sensitivity (B) and specificity (C) by each HPV test to p16-positive OPSCC. Time trend analysis of p16−/HPV+ (D) and p16+/HPV− (E) patients in relation to block year. Incidence before and after 2006 was assessed using logistic regression. Incidence was not assessed for DNA-ISH and RNA-ISH in D, as no patients were found to be p16−/HPV+ using these two assays.